Grant: Collaborative Health Research Projects (NSERC partnered)
University of Toronto
$299,046.00
Development of a lead boron-containing ClpP inhibitor for AML therapy
EF 2014-15
Résumé
Cancer continues to be one of the leading causes of death in the world. This disease is exceptionally complex, which is why it is extremely important to evaluate different angles for therapeutic intervention. This area of modern science involves a number of disciplines, of which chemistry and biology play central roles. While biologists continue to discover new molecular targets that make cancer cell susceptible to treatment, chemists are busy using the results of these studies in order to prepare molecules that can kill cancer cells. The present grant proposal combines the efforts of a renowned cancer hematologist (Schimmer) and a well-known expert in synthetic chemistry (Yudin). Together, the Schimmer and Yudin labs had realized that some of the molecules recently prepared in the Yudin lab can be particularly effective in killing the cancer cells under investigation in the Schimmer lab. As a proof of concept, the two teams were able to show that boron-containing molecules developed by Yudin and his students are particularly well suited to attack proteins that are thought to be present in leukaemia cells. We plan to capitalize on our exciting preliminary results and ensure that our molecules are translated into a clinical asset. In the course of this study, we will also be able to evaluate the significance of our chosen target in cancer therapy. Encouragingly, we have been able to attract interest on behalf of well-known companies (Merck, AstraZeneca, and Anacor), who will help us in our search of effective anti-cancer therapeutics.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
317398
Name
Yudin Andrei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Development of a lead boron-containing ClpP inhibitor for AML therapy
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$299,046
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Acute Myeloid Leukaemia; Amphoteric Molecules; Boron; Cellular Permeability; Clpp Protease; Heterocycles; Mitochondrial Proteasome; Mouse Models; Small Molecules; Structure-Driven Drug Design
Abstract
Cancer continues to be one of the leading causes of death in the world. This disease is exceptionally complex, which is why it is extremely important to evaluate different angles for therapeutic intervention. This area of modern science involves a number of disciplines, of which chemistry and biology play central roles. While biologists continue to discover new molecular targets that make cancer cell susceptible to treatment, chemists are busy using the results of these studies in order to prepare molecules that can kill cancer cells. The present grant proposal combines the efforts of a renowned cancer hematologist (Schimmer) and a well-known expert in synthetic chemistry (Yudin). Together, the Schimmer and Yudin labs had realized that some of the molecules recently prepared in the Yudin lab can be particularly effective in killing the cancer cells under investigation in the Schimmer lab. As a proof of concept, the two teams were able to show that boron-containing molecules developed by Yudin and his students are particularly well suited to attack proteins that are thought to be present in leukaemia cells. We plan to capitalize on our exciting preliminary results and ensure that our molecules are translated into a clinical asset. In the course of this study, we will also be able to evaluate the significance of our chosen target in cancer therapy. Encouragingly, we have been able to attract interest on behalf of well-known companies (Merck, AstraZeneca, and Anacor), who will help us in our search of effective anti-cancer therapeutics.
Competitiondate
201410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Yudin, Andrei; Schimmer, Aaron D
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $299,046~ $0~